Parkinson’s Que Bank

Question 1:
Which of the following drugs requires liver function monitoring due to its potential for hepatotoxicity?

A) Entacapone
B) Pramipexole
C) Tolcapone
D) Selegiline
E) Carbidopa

---

Question 2:
Which drug is primarily metabolized by CYP1A2 and is susceptible to interactions with inducers or inhibitors of this enzyme, such as smoking?

A) Pramipexole
B) Ropinirole
C) Amantadine
D) Levodopa
E) Apomorphine

---

Question 3:
Which of the following drugs is metabolized to amphetamine-like metabolites, potentially leading to drug interactions?

A) Selegiline
B) Rasagiline
C) Entacapone
D) Rotigotine
E) Safinamide

---

Question 4:
Which drug listed is primarily excreted unchanged by the kidneys, necessitating dose adjustments in cases of renal impairment?

A) Pramipexole
B) Rasagiline
C) Safinamide
D) Levodopa
E) Ropinirole

---

Question 5:
Which of the following drugs uses sulfation and glucuronidation as its primary metabolic pathways?

A) Amantadine
B) Apomorphine
C) Rotigotine
D) Safinamide
E) Rasagiline

---

Question 6:
Which drug is metabolized by amidases and CYP3A4, making it susceptible to interactions with other CYP3A4-metabolized drugs?

A) Selegiline
B) Safinamide
C) Entacapone
D) Tolcapone
E) Rotigotine

---

Question 7:
Which drug is combined with Levodopa to inhibit peripheral conversion to dopamine, thereby enhancing its efficacy?

A) Tolcapone
B) Rasagiline
C) Pramipexole
D) Carbidopa
E) Rotigotine

---

Question 8:
Which drug is metabolized mainly by glucuronidation and is used to extend the effect of Levodopa?

A) Rotigotine
B) Safinamide
C) Entacapone
D) Rasagiline
E) Selegiline

---

Question 9:
Which of the following drugs is administered transdermally and undergoes extensive glucuronidation?

A) Amantadine
B) Rotigotine
C) Apomorphine
D) Carbidopa
E) Pramipexole

---

Question 10:
Which of the following motor symptoms is most characteristic of Parkinson’s disease and is often described as a “pill-rolling” motion?

A) Rigidity
B) Akinesia
C) Resting tremor
D) Postural instability
E) Bradykinesia

---

Question 11:
Which of the following symptoms is categorized under non-motor symptoms of Parkinson’s disease and involves a persistent lack of interest or motivation?

A) Rigidity
B) Akinesia
C) Apathy
D) Postural instability
E) Bradykinesia

---

Question 12:
Which of the following motor symptoms of Parkinson’s disease involves slowness of movement, making daily activities like dressing and eating challenging?

A) Tremor
B) Rigidity
C) Bradykinesia
D) Postural instability
E) Dyskinesia

---

Question 13:
Which non-motor symptom of Parkinson’s disease is characterized by excessive or reduced sweating, often leading to difficulties in maintaining body temperature?

A) Apathy
B) Autonomic dysfunction
C) Anosmia
D) Hallucinations
E) Sweating abnormalities

---

Question 14:
Which of the following symptoms is a motor symptom of Parkinson’s disease that involves impaired balance and coordination, increasing the risk of falls?

A) Tremor
B) Rigidity
C) Postural instability
D) Akinesia
E) Dystonia

---

Question 15:
Which non-motor symptom of Parkinson’s disease is associated with mood disturbances such as depression and anxiety?

A) Dementia
B) Apathy
C) Fatigue
D) Mood disorders
E) Anosmia

---

Question 16:
Anosmia, or the loss of smell, is an early non-motor symptom of Parkinson’s disease. Which of the following is true about this symptom?

A) It occurs only in the late stages of Parkinson’s disease
B) It is unrelated to dopamine levels
C) It is often one of the first symptoms to appear
D) It is associated with an improvement in motor symptoms
E) It is caused by a deficiency of acetylcholine

---

Question 17:
Which of the following motor symptoms of Parkinson’s disease is characterized by muscle stiffness and resistance to passive movement?

A) Tremor
B) Akinesia
C) Bradykinesia
D) Rigidity
E) Dyskinesia

---

Question 18:
Visual or auditory hallucinations in Parkinson’s disease are often seen in the later stages. Which neurotransmitter imbalance is primarily responsible for this symptom?

A) Dopamine
B) Serotonin
C) Norepinephrine
D) Glutamate
E) Acetylcholine

---

Question 19:
Orthostatic hypotension is a non-motor symptom of Parkinson’s disease. What is the primary mechanism causing this symptom in Parkinson’s patients?

A) Decreased acetylcholine levels
B) Reduced norepinephrine production
C) Loss of dopamine-producing neurons
D) Excess serotonin activity
E) Increased histamine release

---

Question 20:
What is the primary purpose of combining Levodopa with Carbidopa in the treatment of Parkinson’s disease?

A) To enhance the absorption of Levodopa in the gastrointestinal tract
B) To inhibit the central conversion of Levodopa to dopamine
C) To prevent the peripheral breakdown of Levodopa and increase its availability in the brain
D) To stimulate the production of dopamine in peripheral tissues
E) To reduce the renal excretion of Levodopa

---

Question 21:
Which of the following is a major disadvantage of long-term Levodopa therapy in Parkinson’s disease?

A) Permanent dyskinesias
B) Brown discoloration of the skin
C) Development of the “wearing-off” effect
D) Complete resistance to the drug over time
E) Hyperpigmentation of the skin

---

Question 22:
Which of the following is a peripheral side effect of Levodopa therapy?

A) Dyskinesias
B) Hallucinations
C) Orthostatic hypotension
D) Delusions
E) Vivid dreams

---

Question 23:
Which of the following describes the “on-off” effect associated with Levodopa therapy?

A) Sudden and unpredictable fluctuations between periods of good and poor motor control
B) Gradual loss of drug effectiveness requiring higher doses
C) Persistent dyskinesias throughout the treatment period
D) Continuous improvement in symptoms without fluctuation
E) Sudden onset of hallucinations followed by confusion

---

Question 24:
Which of the following motor complications can result from excessive Levodopa therapy?

A) Akinesia
B) Rigidity
C) Dyskinesias
D) Bradykinesia
E) Tremors

---

Question 25:
What is a common neuropsychiatric side effect of Levodopa, particularly in elderly patients?

A) Severe depression
B) Neuroleptic malignant syndrome
C) Vivid dreams and hallucinations
D) Anorexia and weight loss
E) Hyperactivity and insomnia

---

Question 26:
Why is Levodopa not typically used to treat Parkinsonism associated with antipsychotic drug therapy?

A) It is ineffective in treating Parkinsonism caused by antipsychotics
B) It can exacerbate psychosis symptoms
C) It interacts negatively with all antipsychotic drugs
D) It causes irreversible movement disorders
E) It leads to severe cardiovascular side effects

---

Question 27:
Brown discoloration of saliva and urine is a side effect of Levodopa therapy. What is the cause of this discoloration?

A) Accumulation of unmetabolized Levodopa
B) Dopamine degradation
C) Oxidation of catecholamines
D) Presence of blood in the urine
E) Bile pigments

---

Question 28:
Which of the following dopamine agonists is specifically indicated for both Parkinson’s disease and Restless Legs Syndrome (RLS) and may cause impulse control disorders as a serious side effect?

A) Pramipexole
B) Bromocriptine
C) Pergolide
D) Apomorphine
E) Rotigotine

---

Question 29:
Which of the following side effects is commonly associated with the use of dopamine agonists like Ropinirole and can be particularly concerning for patients who drive or operate heavy machinery?

A) Sudden sleep onset
B) Hypersexuality
C) Orthostatic hypotension
D) Hallucinations
E) Syncope

---

Question 30:
Bromocriptine is used in the management of several conditions, including Parkinson’s disease and hyperprolactinemia. Which of the following is a rare but serious side effect associated with long-term use of Bromocriptine?

A) Impulse control disorders
B) Sudden sleep onset
C) Pulmonary fibrosis
D) Orthostatic hypotension
E) Skin reactions

---

Question 31:
Which of the following dopamine agonists is administered via a transdermal patch and is known to cause skin reactions at the application site?

A) Pramipexole
B) Bromocriptine
C) Rotigotine
D) Ropinirole
E) Apomorphine

---

Question 32:
Which dopamine agonist, when used in combination with Levodopa in advanced Parkinson’s disease, helps to reduce the required Levodopa dosage and manage motor fluctuations?

A) Apomorphine
B) Bromocriptine
C) Ropinirole
D) Pergolide
E) Pramipexole

---

Question 33:
Which of the following side effects is common to all dopamine agonists and involves changes in behavior such as compulsive gambling or shopping?

A) Hallucinations
B) Impulse control disorders
C) Orthostatic hypotension
D) Drowsiness
E) Nausea

---

Question 34:
Why are dopamine agonists often used as an initial monotherapy in younger patients with early-stage Parkinson’s disease?

A) They are more effective than Levodopa in all cases
B) They delay the onset of Levodopa-induced complications
C) They have no side effects
D) They do not require titration
E) They are less expensive than Levodopa

---

Question 35:
Which of the following dopamine agonists has a nonselective action on D1 and D2 receptors and is used as a rescue therapy for “off” episodes in Parkinson’s disease?

A) Pramipexole
B) Apomorphine
C) Rotigotine
D) Bromocriptine
E) Ropinirole

---

Question 36:
Which of the following is an irreversible inhibitor of monoamine oxidase-B (MAO-B) used in the treatment of Parkinson’s disease?

A) Safinamide
B) Selegiline
C) Entacapone
D) Tolcapone
E) Opicapone

---

Question 37:
Which of the following MAO-B inhibitors does not metabolize into amphetamine-like substances, thereby reducing the risk of insomnia?

A) Selegiline
B) Rasagiline
C) Safinamide
D) Entacapone
E) Tolcapone

---

Question 38:
Which of the following side effects is a serious concern when taking MAO-B inhibitors along with tyramine-rich foods?

A) Serotonin syndrome
B) Orthostatic hypotension
C) Hypertensive crisis
D) Hallucinations
E) Rhabdomyolysis

---

Question 39:
Which of the following COMT inhibitors is associated with a significant risk of liver toxicity and requires regular liver function monitoring?

A) Entacapone
B) Tolcapone
C) Opicapone
D) Selegiline
E) Safinamide

---

Question 40:
What is the primary therapeutic use of COMT inhibitors in the management of Parkinson’s disease?

A) Monotherapy in early-stage Parkinson’s disease
B) Adjunctive therapy to reduce “wearing-off” symptoms with Levodopa/carbidopa
C) Treatment of neuroleptic malignant syndrome
D) Management of dyskinesias
E) Treatment of Restless Legs Syndrome

---

Question 41:
Which of the following is a common but harmless side effect of Entacapone, a COMT inhibitor?

A) Urine discoloration
B) Severe headaches
C) Anaphylactic reactions
D) Extreme fatigue
E) Profound hypotension

---

Question 42:
Serotonin syndrome is a potential risk when MAO-B inhibitors are combined with which of the following types of drugs?

A) Anticholinergics
B) Serotonergic drugs (e.g., SSRIs, SNRIs)
C) Beta-blockers
D) Antihistamines
E) Nonsteroidal anti-inflammatory drugs (NSAIDs)

---

Question 43:
Which MAO-B inhibitor is reversible and may offer a lower risk of drug interactions compared to irreversible inhibitors?

A) Selegiline
B) Rasagiline
C) Safinamide
D) Entacapone
E) Tolcapone

---

Question 44:
Which serious side effect is specifically associated with the use of Tolcapone and requires careful monitoring?

A) Pulmonary fibrosis
B) Liver toxicity
C) Renal failure
D) Cardiac arrhythmias
E) Retinal damage

---

Question 45:
Why are COMT inhibitors like Entacapone not effective as monotherapy in Parkinson’s disease?

A) They do not cross the blood-brain barrier
B) They require the presence of Levodopa to exert their effect
C) They cause severe hypotension
D) They are rapidly metabolized and excreted
E) They are only effective in advanced stages of the disease

---

Question 46:
What is the primary therapeutic use of anticholinergic medications like Benztropine and Trihexyphenidyl in Parkinson’s disease?

A) To enhance dopamine production
B) To manage tremors and rigidity
C) To improve cognitive function
D) To reduce dyskinesias
E) To alleviate depression

---

Question 47:
Which of the following side effects is commonly associated with anticholinergic medications and involves difficulty in emptying the bladder?

A) Tachycardia
B) Urinary retention
C) Constipation
D) Mydriasis
E) Dry mouth

---

Question 48:
Which of the following conditions is a contraindication for the use of anticholinergic drugs in patients?

A) Parkinson’s disease
B) Breastfeeding mothers
C) Urinary incontinence
D) Hypertension
E) Bradycardia

---

Question 49:
Which of the following is an NMDA receptor antagonist that is used to manage Levodopa-induced dyskinesias in Parkinson’s disease?

A) Benztropine
B) Trihexyphenidyl
C) Amantadine
D) Selegiline
E) Rasagiline

---

Question 50:
Which of the following side effects is associated with Amantadine and involves swelling of the lower limbs?

A) Cognitive impairment
B) Peripheral edema
C) Orthostatic hypotension
D) Cardiac arrhythmias
E) Dry mouth

---

Question 51:
Which of the following statements is true regarding the use of Amantadine in patients with renal impairment?

A) Amantadine does not require any dose adjustment
B) Amantadine is primarily metabolized by the liver
C) Amantadine requires dose adjustment due to renal excretion
D) Amantadine is contraindicated in all patients with renal impairment
E) Amantadine is excreted through the lungs

---

Question 52:
Which of the following cognitive side effects might be exacerbated by the use of Amantadine in elderly patients with Parkinson’s disease?

A) Improved memory
B) Increased alertness
C) Confusion and hallucinations
D) Enhanced cognitive function
E) Improved concentration

---

Question 53:
Which of the following mechanisms is involved in the therapeutic action of NMDA receptor antagonists like Amantadine?

A) Inhibition of dopamine reuptake
B) Enhancement of acetylcholine activity
C) Blocking of NMDA receptors to reduce excitotoxicity
D) Inhibition of MAO-B enzymes
E) Stimulation of serotonin receptors

---

Question 54:
Which of the following side effects is specifically associated with the use of anticholinergic drugs in the management of Parkinson’s disease and can affect the eyes?

A) Mydriasis
B) Miosis
C) Glaucoma
D) Cataracts
E) Retinal detachment

---

Some case-type questions

Case 1:

Mr. J, a 62-year-old male, comes to the pharmacy with a new prescription for Ropinirole. Upon reviewing his profile, you notice that there is no mention of Levodopa in his current medications or past prescriptions. He mentions that he was recently diagnosed with Parkinson’s disease and this is the first medication he has been prescribed for it.

Question 1:
As the pharmacist, what is the most likely reason Ropinirole has been prescribed as monotherapy for Mr. J?

A) To manage mild symptoms of Parkinson’s disease in the early stages
B) To treat Restless Legs Syndrome (RLS)
C) To avoid the side effects associated with Levodopa in elderly patients
D) To prevent the progression of Parkinson’s disease
E) To alleviate cognitive symptoms associated with Parkinson’s disease

Correct Answer: A) To manage mild symptoms of Parkinson’s disease in the early stages
Explanation: Ropinirole is often prescribed as monotherapy in the early stages of Parkinson’s disease to manage mild symptoms, particularly in younger patients, to delay the initiation of Levodopa and reduce the risk of Levodopa-induced complications.

Follow-up Question:
Mr. J asks if there are any side effects he should be particularly aware of with Ropinirole. Which of the following side effects should you counsel him on?

A) Severe nausea and vomiting
B) Sudden sleep onset and impulse control disorders
C) Significant weight loss
D) Hypertensive crisis
E) Severe joint pain

Correct Answer: B) Sudden sleep onset and impulse control disorders
Explanation: Ropinirole can cause sudden sleep onset and impulse control disorders, such as compulsive gambling or shopping, which are important side effects to discuss with the patient.

---

Case 2:

Mrs. L, a 68-year-old female, comes to the pharmacy with a new prescription for Entacapone. Upon reviewing her medication history, you notice that she is currently taking Levodopa/Carbidopa for her Parkinson’s disease. This is her first time being prescribed Entacapone.

Question 1:
What is the most likely reason Mrs. L has been prescribed Entacapone along with her Levodopa/Carbidopa therapy?

A) To enhance the absorption of Levodopa in the gastrointestinal tract
B) To extend the duration of Levodopa’s effect and manage “wearing-off” symptoms
C) To increase dopamine synthesis in the brain
D) To reduce the risk of dyskinesias associated with Levodopa
E) To prevent orthostatic hypotension

Correct Answer: B) To extend the duration of Levodopa’s effect and manage “wearing-off” symptoms
Explanation: Entacapone is a COMT inhibitor that is used to extend the duration of Levodopa’s effect by preventing its breakdown. This helps manage “wearing-off” symptoms in patients with Parkinson’s disease.

Follow-up Question:
Mrs. L asks if there are any side effects specific to Entacapone that she should be aware of. Which of the following side effects should you counsel her about?

A) Severe liver toxicity
B) Harmless reddish-brown discoloration of urine
C) Sudden onset of confusion
D) Increased risk of hypertension
E) Severe joint pain

Correct Answer: B) Harmless reddish-brown discoloration of urine
Explanation: Entacapone can cause a harmless reddish-brown discoloration of the urine, which is a common and benign side effect that patients should be made aware of.

---

Case 3:

Mr. D, a 70-year-old male, comes to the pharmacy with a new prescription for Entacapone. Upon reviewing his medication history, you notice that there is no mention of Levodopa in his current medications or past prescriptions. This is his first time being prescribed Entacapone.

Question 1:
As the pharmacist, what would be the most appropriate course of action in this situation?

A) Dispense the Entacapone as prescribed
B) Contact the prescriber to confirm the prescription
C) Substitute Entacapone with a different Parkinson’s medication
D) Advise the patient to take Entacapone alone as monotherapy
E) Recommend an over-the-counter supplement to enhance Entacapone’s effect

Correct Answer: B) Contact the prescriber to confirm the prescription
Explanation: Entacapone is not effective as monotherapy for Parkinson’s disease; it is used in combination with Levodopa to enhance its effect by preventing its breakdown. Since there’s no mention of Levodopa in the prescription or the patient’s profile, it’s essential to contact the prescriber to clarify and confirm the intended treatment plan.

Follow-up Question:
If the prescriber confirms that the prescription for Entacapone was an error and was intended to be prescribed with Levodopa, what should your next step be?

A) Dispense Entacapone and instruct the patient to take it with their current medications
B) Refuse to fill the prescription and refer the patient to another pharmacy
C) Ask the prescriber to send a corrected prescription that includes both Levodopa and Entacapone
D) Dispense the Entacapone and advise the patient to start Levodopa later
E) Substitute Entacapone with an alternative medication

Correct Answer: C) Ask the prescriber to send a corrected prescription that includes both Levodopa and Entacapone
Explanation: The appropriate step is to ask the prescriber to send a corrected prescription that includes both Levodopa and Entacapone, as Entacapone should only be used in combination with Levodopa for the treatment of Parkinson’s disease.

---

Case 4:

Mrs. K, a 65-year-old female with Parkinson’s disease, comes to the pharmacy with a new prescription for Selegiline. She is also taking Sertraline, an SSRI, for depression.

Question 1:
As the pharmacist, what potential risk should you be most concerned about with this combination of medications?

A) Worsening of Parkinson’s symptoms
B) Development of serotonin syndrome
C) Increased risk of orthostatic hypotension
D) Decreased efficacy of Selegiline
E) Increased risk of gastrointestinal bleeding

Correct Answer: B) Development of serotonin syndrome
Explanation: Selegiline is an MAO-B inhibitor, and when combined with an SSRI like Sertraline, there is a risk of developing serotonin syndrome, a potentially life-threatening condition characterized by high levels of serotonin. It’s important to alert the prescriber to this risk.

---

Case 5:

Mr. T, a 70-year-old male with Parkinson’s disease, has been prescribed Rasagiline. He mentions that he regularly enjoys aged cheeses and cured meats.

Question 1:
What potential risk should you counsel Mr. T about with his new Rasagiline prescription?

A) Increased risk of tremors
B) Development of hypertensive crisis
C) Onset of hallucinations
D) Increased risk of dyskinesias
E) Development of glaucoma

Correct Answer: B) Development of hypertensive crisis
Explanation: Rasagiline is an MAO-B inhibitor, and consuming large amounts of tyramine-rich foods like aged cheeses and cured meats while on this medication can lead to a hypertensive crisis, which is a potentially life-threatening increase in blood pressure.

Follow-up Question:
What dietary advice should you provide to Mr. T to prevent the risk of hypertensive crisis?

A) Increase intake of high-fiber foods
B) Avoid all dairy products
C) Limit or avoid foods high in tyramine, such as aged cheeses and cured meats
D) Drink plenty of fluids throughout the day
E) Avoid all citrus fruits

Correct Answer: C) Limit or avoid foods high in tyramine, such as aged cheeses and cured meats
Explanation: Mr. T should be advised to limit or avoid foods high in tyramine, such as aged cheeses and cured meats, while taking Rasagiline to prevent the risk of a hypertensive crisis.

---

Case 6:

Mr. L, a 68-year-old male, recently diagnosed with Parkinson’s disease, has been started on Levodopa/Carbidopa therapy. After a few days of starting the treatment, he returns to the pharmacy complaining of persistent nausea that has made it difficult for him to continue with the medication.

Question 1:
What is the most likely cause of Mr. L’s nausea?

A) Dopamine-induced activation of the chemoreceptor trigger zone (CTZ)
B) Inadequate dosing of Levodopa
C) Allergic reaction to Carbidopa
D) Onset of a gastrointestinal infection
E) Drug-induced gastritis

Correct Answer: A) Dopamine-induced activation of the chemoreceptor trigger zone (CTZ)
Explanation: The nausea Mr. L is experiencing is likely due to dopamine-induced activation of the chemoreceptor trigger zone (CTZ) in the medulla, a common side effect of Levodopa/Carbidopa therapy.

Follow-up Question 1:
Which of the following management strategies would be most appropriate to help reduce Mr. L’s nausea?

A) Increase the dose of Levodopa/Carbidopa
B) Take the medication with a high-protein meal
C) Add an antiemetic such as Domperidone
D) Discontinue the Levodopa/Carbidopa therapy
E) Switch to another Parkinson’s medication immediately

Correct Answer: C) Add an antiemetic such as Domperidone
Explanation: Adding an antiemetic such as Domperidone can help reduce nausea by blocking dopamine receptors in the periphery, which helps prevent activation of the chemoreceptor trigger zone without affecting the central action of Levodopa. Domperidone is preferred because it does not cross the blood-brain barrier and thus does not interfere with dopamine activity in the brain. Alternatives: Ondansetron – 5 HT3 receptor antagonist, Trimethobenzamide – acts on CTZ.

Follow-up Question 2:
Which of the following antiemetic drugs should be avoided in Mr. L due to its potential to worsen Parkinson’s symptoms?

A) Ondansetron
B) Metoclopramide
C) Prochlorperazine
D) Domperidone
E) Promethazine

Correct Answer: B) Metoclopramide
Explanation: Metoclopramide should be avoided in patients with Parkinson’s disease because it is a dopamine antagonist that crosses the blood-brain barrier and can worsen Parkinson’s symptoms by blocking dopamine receptors in the brain. Other dopamine antagonists, such as Prochlorperazine and Promethazine, should also be avoided for the same reason. These drugs can exacerbate motor symptoms in Parkinson’s patients and should be replaced with safer alternatives, such as Ondansetron, which does not affect dopamine receptors.

---

Case 7:

Mr. R, a 72-year-old male with a history of Parkinson’s disease and benign prostatic hyperplasia (BPH), comes to the pharmacy with a new prescription for Trihexyphenidyl, an anticholinergic medication prescribed to help manage his Parkinson’s tremors.

Question 1:
As the pharmacist, what potential concern should you have regarding the use of Trihexyphenidyl in this patient?

A) Worsening of Parkinson’s symptoms
B) Exacerbation of BPH symptoms
C) Increased risk of gastrointestinal bleeding
D) Onset of serotonin syndrome
E) Development of neuroleptic malignant syndrome

Correct Answer: B) Exacerbation of BPH symptoms
Explanation: Trihexyphenidyl is an anticholinergic medication, which can exacerbate symptoms of BPH by causing urinary retention. This could worsen Mr. R’s BPH symptoms, leading to difficulties with urination.

Follow-up Question:
Which class of Parkinson’s medications would be most appropriate for Mr. R to avoid exacerbating his BPH symptoms?

A) Dopamine agonists (e.g., Ropinirole)
B) MAO-B inhibitors (e.g., Selegiline)
C) Anticholinergics (e.g., Benztropine)
D) NMDA receptor antagonists (e.g., Amantadine)
E) COMT inhibitors (e.g., Entacapone)

Correct Answer: A) Dopamine agonists (e.g., Ropinirole)
Explanation: Dopamine agonists, such as Ropinirole, are appropriate for treating Parkinson’s disease in patients with BPH as they do not have the anticholinergic effects that could worsen urinary retention. Anticholinergics, like Trihexyphenidyl and Benztropine, should be avoided in this scenario due to their potential to exacerbate BPH symptoms.

---

Case 8:

A 68-year-old male patient with schizophrenia has been treated with Haloperidol for the past six months. He recently started experiencing tremors, rigidity, and bradykinesia. His family is concerned that he might be developing Parkinson’s disease. However, upon reviewing his medication history, you suspect these symptoms may be related to his current treatment.

Which of the following is the most likely cause of this patient’s symptoms?

A) Natural progression of Parkinson’s disease
B) Secondary parkinsonism induced by Haloperidol
C) Drug interaction between Haloperidol and another medication
D) Underlying neurological condition unrelated to medication
E) Normal aging process

Correct Answer: B) Secondary parkinsonism induced by Haloperidol
Explanation: Haloperidol, a typical antipsychotic, is known to block dopamine receptors, which can lead to secondary parkinsonism. The patient’s tremors, rigidity, and bradykinesia are likely related to this drug-induced condition rather than the natural progression of Parkinson’s disease. Discontinuation or adjustment of the medication should be considered to alleviate these symptoms.

---

Case 9:

A 65-year-old male with a history of Parkinson’s disease is being treated with Carbidopa/Levodopa. Recently, his neurologist added a new medication to his regimen to help manage his motor symptoms. A few weeks after starting the new medication, the patient begins exhibiting symptoms of increased energy, reduced need for sleep, and impulsive behaviors, such as gambling and excessive spending.

Which of the following antiparkinsonian medications is most likely responsible for inducing these symptoms?

A) Selegiline
B) Entacapone
C) Pramipexole
D) Amantadine
E) Carbidopa

Correct Answer: C) Pramipexole
Explanation: Pramipexole is a dopamine agonist commonly used in the treatment of Parkinson’s disease. It is known to potentially induce impulse control disorders, including behaviors such as compulsive gambling, hypersexuality, and excessive spending. These side effects are linked to the overstimulation of dopamine receptors, particularly in the mesolimbic pathway, which is associated with reward and impulse control.